(15:44 GMT) Viridian Therapeutics Price Target Raised to $35.00/Share From $34.00 by RBC Capital
DO Dow Jones Newswires Viridian Therapeutics Is Maintained at Outperform by RBC Capital 6/30/2026, 11:44 PM GMT+8 Dow Jones Newswires VR VRDN (15:44 GMT) Viridian Therapeutics Price Target Raised to $35.00/Share From $34.00 by RBC Capital Market News Zacks VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know Dow Jones Newswires Viridian Therapeutics Is Maintained at Buy by Truist Securities Dow Jones Newswires Viridian Therapeutics Is Maintained at Outperform by Wedbush Dow Jones Newswires Viridian Therapeutics Is Maintained at Buy by Needham
